WASHINGTON (AP) — Shares of drugmaker Gilead Sciences Inc. hit an all-time high in trading Tuesday after the company released overwhelmingly positive results for an experimental hepatitis C drug that analysts say could be a best-in-class medication.

Over the weekend Gilead presented results from its combination of sofosbuvir and daclatasvir that cured between 98 and 100 percent of patients within 12 weeks.

About 3.2 million people in the United States have hepatitis C, a blood-borne disease linked to 12,000 U.S. deaths a year. The traditional two-drug treatment for the virus cures only about 40 percent of people and causes side effects like nausea, fatigue and vomiting.

Read the full story